MarginsXMarginsX
Home › Markets › Health Care › ARQT

Arcutis Biotherapeutics Inc. (ARQT)

ARQT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$27.15
-3.93% on the day
Market cap
$3.4B
Mid cap
Revenue · 2025
$376.1M
+91.3% on 2024
Net income · 2025
-$16.1M
-4.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/0001787306-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerARQT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001787306
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$376.1M
Net income-$16.1M
Operating income-$12.2M
Net margin-4.3%
Operating margin-3.3%
Revenue growth+91.3%
Cash$42.9M
Total assets$433.0M
P/E (computed)Net income was not positive
P/S (computed)9.1×

Warning signs

Cash runway
Cash-flow positive
$33.4M cash at September 30, 2026
Share count, 1 year
+3.2%
2025-10-22 to 2026-10-30 · +34.0% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$17.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$33.4M cash; operating cash flow $15.0M a quarter.Report 2026-09-30
Shares outstanding126,455,033 (2026-10-30); 122,492,192 a year earlier; 94,382,074 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-11-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Los Angeles, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $17.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$143.9M$8.8M$18.9M$33.4M$109.4M$508.7M10-Q 2026-11-04
Q2 2026
2026-06-30
$129.9M$15.0M$12.6M$34.1M$108.9M$464.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$105.4M-$11.3M$2.2M$34.8M$109.4M$415.6M10-Q 2026-05-06
Q4 2025
2025-12-31
$129.5M$17.4M$26.2M$42.9M$109.0M$376.1M10-K 2026-02-25
Q3 2025
2025-09-30
$99.2M$7.4M-$1.8M$47.1M$108.5M$317.9M10-Q 2026-11-04
Q2 2025
2025-06-30
$81.5M-$15.9M$324K$72.7M$108.0M$263.5M10-Q 2026-08-05
Q1 2025
2025-03-31
$65.8M-$25.1M-$30.4M$53.1M$107.6M$212.8M10-Q 2026-05-06
Q4 2024
2024-12-31
$71.4M-$10.8M-$748K$71.3M$107.2M$196.5M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-04
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 868 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+10.6%
1 month+8.3%
3 months+9.4%
Year to date-2.7%
1 year+23.6%
From 52-week high-17.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
OGNOrganon & Co. Common Stock$13.900.00%$3.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier